Neurosurgeons from Germany and USA report on their clinical experience of using Nexstim NBS system

Helsinki, Finland: 31 January 2017 - Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company with a pioneering navigated non-invasive brain stimulation system, announces that, in a recently published clinical article, neurosurgeons report clinical benefits of using Nexstim NBS Brain Mapping technology, for pre-surgical localization of the motor cortex.

In a recent multi-center study at Departments of Neurosurgery at Charite Univärsitetsmedizin, Berlin, Teknische Universität Munchen and University of California San Francisco outcomes of brain surgery performed because of tumor metastases in the central brain areas were compared between two observational patient cohorts. Cohort 1 included 120 consecutive patients in whom preoperative localization of the motor cortex in relation to the metastasis was performed with Nexstim NBS system. Cohort 2 included 130 consecutive patients in whom NBS motor mapping was not performed because of organizational issues.

More info on Nexstim's website


Next > Green Biologics acquires GreenFlame™ Brand, Inks Kroger as first retail partner for sustainable charcoal lighter fluid

Previous > Mainstay confirms its continued eligibility to the PEA-PME